Imuran coated tablets 50 mg. №100

$179.00

Manufacturer: Germany

Purpose: Suppresses immune response; treats autoimmune diseases like rheumatoid arthritis.

SKU: MED58847 Category:

Description

Imuran Coated Tablets 50 mg. №100

Ingredients

Active ingredient: Azathioprine.
Other ingredients: Lactose, maize starch, povidone, and magnesium stearate.

Dosage

Dosage: The usual dose ranges from 1 to 3 mg per kg of body weight per day, taken as a single dose or divided into two doses.

Indications

Imuran tablets are indicated for:

  • Prevention of rejection in organ transplantation.
  • Treatment of rheumatoid arthritis.
  • Management of severe psoriasis.

Contraindications

Do not use Imuran tablets if:

  • You are allergic to azathioprine or any other ingredients.
  • You have a history of bone marrow suppression.
  • You are pregnant or breastfeeding.

Directions

Directions for use: Swallow the tablets whole with a full glass of water. Do not crush or chew the tablets.

Scientific Evidence

Scientific studies have shown that Imuran:

1. Reduces the risk of rejection in organ transplant recipients.
2. Helps in the management of autoimmune diseases like rheumatoid arthritis by suppressing the immune response.
3. Is effective in treating severe psoriasis by inhibiting DNA synthesis in rapidly dividing cells.

Additional Information

Storage: Store Imuran tablets at room temperature away from moisture and heat.

Warnings: Imuran may increase the risk of developing certain types of cancer. Consult your doctor for more information.

Imuran works by interfering with the synthesis of DNA in immune cells, thereby reducing their activity. This helps in preventing the rejection of transplanted organs and suppressing the abnormal immune response seen in autoimmune diseases.

Clinical trials have demonstrated the efficacy of Imuran in maintaining long-term graft survival in organ transplant recipients. Additionally, studies have shown that Imuran, when used in combination with other immunosuppressive agents, can improve outcomes in patients with autoimmune conditions.